Advanced search
Publication Cover
Leukemia & Lymphoma Volume 53, 2012 - Issue 10
Submit an article Journal homepage
412
Views
18
CrossRef citations to date
0
Altmetric
Letters to the Editor

Persistence of CD30 expression in Hodgkin lymphoma following brentuximab vedotin (SGN-35) treatment failure

Nitya NathwaniDepartment of Hematology/HCT
,
Amrita Y. KrishnanDepartment of Hematology/HCT
,
Qin HuangDepartment of Pathology, City of Hope, Duarte, CA, USA
,
Young KimDepartment of Pathology, City of Hope, Duarte, CA, USA
,
Chatchada KaranesDepartment of Hematology/HCT
,
Eileen P. SmithDepartment of Hematology/HCT
,
Stephen J. FormanDepartment of Hematology/HCT
,
Eric SieversSeattle Genetics, Bothell, WA, USA
,
Sandra H. ThomasDepartment of Hematology/HCT
&
Robert W. ChenDepartment of Hematology/HCTCorrespondence[email protected]
 show all
Pages 2051-2053 | Received 23 Dec 2011, Accepted 06 Feb 2012, Published online: 18 Apr 2012

Citations (18)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Árpád Illés, Ádám Jóna & Zsófia Miltényi. (2015) Brentuximab vedotin for treating Hodgkin’s lymphoma: an analysis of pharmacology and clinical efficacy. Expert Opinion on Drug Metabolism & Toxicology 11:3, pages 451-459.
Read now

Articles from other publishers (17)

Natalie S. Grover, Christopher Dittus, Astha Thakkar & Anne W. Beaven. (2023) The optimal management of relapsed and refractory Hodgkin lymphoma: post–brentuximab and checkpoint inhibitor failure. Hematology 2023:1, pages 510-518.
Crossref
Mary L. Faber, Robyn A. A. Oldham, Archana Thakur, Mary Jo Rademacher, Ewa Kubicka, Theresa A. Dlugi, Steven A. Gifford, William M. McKillop, Nathan J. Schloemer, Lawrence G. Lum & Jeffrey A. Medin. (2023) Novel anti-CD30/CD3 bispecific antibodies activate human T cells and mediate potent anti-tumor activity. Frontiers in Immunology 14.
Crossref
Mario L. Marques‐Piubelli, Do Hwan Kim, L. Jeffrey Medeiros, Wei Lu, Khaja Khan, Lorena Isabel Gomez‐Bolanos, Saxon Rodriguez, Edwin R. Parra, Chi Young Ok, Akanksha Aradhya, Luisa M Solis, Yago L. Nieto, Raphael Steiner, Sairah Ahmed & Francisco Vega. (2023) CD30 expression is frequently decreased in relapsed classic Hodgkin lymphoma after anti‐CD30 CAR T‐cell therapy . Histopathology 83:1, pages 143-148.
Crossref
Damian T. Rieke & Ulrich Keller. (2020) A CD205-directed antibody drug conjugate – lymphoma precision oncology or sophisticated chemotherapy?. Haematologica 105:11, pages 2504-2506.
Crossref
Jason GotlibJohn H. Baird, Tracy I. George, Cheryl LangfordIsabel ReyesJustin AbuelCecelia PerkinsKurt Schroeder, Prithviraj Bose & Srdan Verstovsek. (2019) A phase 2 study of brentuximab vedotin in patients with CD30-positive advanced systemic mastocytosis. Blood Advances 3:15, pages 2264-2271.
Crossref
Jacqueline N. Poston, Jonathan R. Fromm, Heather A. Rasmussen, Andrei R. Shustov, Edward N. LibbyIIIIII, Stephen D. Smith, Ted Gooley & Ajay K. Gopal. (2018) A pilot study of weekly brentuximab vedotin in patients with CD 30+ malignancies resistant to brentuximab vedotin every 3 weeks . British Journal of Haematology 186:1, pages 159-162.
Crossref
C A van der Weyden, S A Pileri, A L Feldman, J Whisstock & H M Prince. (2017) Understanding CD30 biology and therapeutic targeting: a historical perspective providing insight into future directions. Blood Cancer Journal 7:9, pages e603-e603.
Crossref
Frank Loganzo, Matthew Sung & Hans-Peter Gerber. (2016) Mechanisms of Resistance to Antibody–Drug Conjugates. Molecular Cancer Therapeutics 15:12, pages 2825-2834.
Crossref
Shinichi Makita, Akiko Miyagi Maeshima, Hirokazu Taniguchi, Hideaki Kitahara, Suguru Fukuhara, Wataru Munakata, Tatsuya Suzuki, Dai Maruyama, Yukio Kobayashi & Kensei Tobinai. (2016) Classical Hodgkin lymphoma primary refractory to brentuximab vedotin, with transformation to CD30-positive diffuse large B-cell lymphoma. International Journal of Hematology 104:3, pages 396-399.
Crossref
Uma Borate, Amitkumar Mehta, Vishnu Reddy, Michaela Tsai, Neil Josephson & Ian Schnadig. (2016) Treatment of CD30-positive systemic mastocytosis with brentuximab vedotin. Leukemia Research 44, pages 25-31.
Crossref
Larisa J. Geskin. (2015) Monoclonal Antibodies. Dermatologic Clinics 33:4, pages 777-786.
Crossref
Robert Chen, Jessie Hou, Edward Newman, Young Kim, Cecile Donohue, Xueli Liu, Sandra H. Thomas, Stephen J. Forman & Susan E. Kane. (2015) CD30 Downregulation, MMAE Resistance, and MDR1 Upregulation Are All Associated with Resistance to Brentuximab Vedotin . Molecular Cancer Therapeutics 14:6, pages 1376-1384.
Crossref
Solomon A. Graf & Ajay K. Gopal. (2014) Treatment of relapsed classical Hodgkin lymphoma in the brentuximab vedotin era. Hematology 2014:1, pages 151-157.
Crossref
Niels W.C.J. van de Donk & Eugen Dhimolea. 2014. Handbook of Therapeutic Antibodies. Handbook of Therapeutic Antibodies 1417 1444 .
Denise Hollman-Hewgley, Michael Lazare, Alex Bordwell, Emily Zebadua, Pinky Tripathi, Alexander S. Ross, Deanna Fisher, Alisha Adams, Derek Bouman, Dennis P. O’Malley & Lawrence M. Weiss. (2014) A Single Slide Multiplex Assay for the Evaluation of Classical Hodgkin Lymphoma. American Journal of Surgical Pathology 38:9, pages 1193-1202.
Crossref
Matthew Mei, Sandra Thomas & Robert Chen. (2013) Management of Relapsed or Refractory Hodgkin Lymphoma with Second-Generation Antibody–Drug Conjugates: Focus on Brentuximab Vedotin. BioDrugs 28:3, pages 245-251.
Crossref
Lawrence M. Weiss. (2013) Atypical Phenotypes in Classical Hodgkin Lymphoma. Surgical Pathology Clinics 6:4, pages 729-742.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.